UBS lowered the firm’s price target on Inspire Medical (INSP) to $67 from $89 and keeps a Neutral rating on the shares. The 2026 guidance was lowered under the additional pressure given recent coding dynamics, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Inspire Medical downgraded to Peer Perform from Outperform at Wolfe Research
- Inspire Medical Weighs Growth Against Reimbursement Risks
- Shopify upgraded, Coinbase downgraded: Wall Street’s top analyst calls
- Inspire Medical price target lowered to $68 from $90 at RBC Capital
- Inspire Medical price target lowered to $95 from $110 at Stifel